Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial

TY - JOUR

T1 - Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial

AU - The LEADER Publication Committee on behalf of the LEADER Trial Investigators

AU - Verma, Subodh

AU - Leiter, Lawrence A.

AU - David Mazer, C.

AU - Bain, Stephen C.

AU - Buse, John

AU - Marso, Steve

AU - Nauck, Michael

AU - Zinman, Bernard

AU - Bosch-Traberg, Heidrun

AU - Rasmussen, Søren

AU - Michelsen, Marie M.

AU - Bhatt, Deepak L.

N1 - Funding Information: Dr Verma reports research grants and/or speaking honoraria from Boehringer Ingelheim/Eli Lilly, AstraZeneca, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Valeant, and Amgen. Dr Leiter reports consultant and speaker fees from Am-gen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, and Servier; consultant fees from Regeneron; and research grants or support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion, GlaxoSmithKline, Janssen, Kowa, Merck, Novartis, Novo Nordisk, Resverlogix, Sanofi, and The Medicines Company. Dr Mazer reports consulting fees from Amgen, Boehringer Ingelheim, and OctaPharma. Dr Bain reports research grants from Healthcare and Research Wales (Welsh government) and Novo Nordisk; other research and infrastructure support from Healthcare and Research Wales (Welsh government); honoraria from Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim, and Merck; and ownership interest in Glycosme-dia (diabetes online news service). Dr Buse reports consulting fees paid to his institution and travel support from Adocia, AstraZeneca, Dexcom, Elcelyx Therapeutics, Eli Lilly, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Sanofi, Senseonics, and vTv Therapeutics; grant support from AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lexicon, Novo Nordisk, Sanofi, Theracos, vTv Therapeutics, and the National Institutes of Health (UL1TR002489); and stock options from Mellitus Health, PhaseBio, and Stability Health. Dr Marso reports consulting fees from Novo Nordisk and St. Jude Medical and research support from Novo Nordisk, Terumo, The Medicines Company, AstraZeneca, and Bristol Myers-Squibb. Dr Nauck reports advisory board membership or consultancy for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and Novo Nordisk, as well as speakers’ bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and Novo Nordisk A/S. His institution has received grant support from AstraZeneca, Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and Novo Nordisk A/S. Dr Zinman reports consulting fees from Merck, Novo Nordisk, Sanofi-Aventis, Eli Lilly, AstraZeneca, Janssen, and Boehringer Ingelheim. Drs Bosch-Traberg and Rasmussen are Novo Nordisk employees and shareholders. Dr Michelsen is a Novo Nordisk employee. Dr Bhatt reports advisory board for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Re-gado Biosciences; Board of Directors for Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair of the American Heart Association Quality Oversight Committee; Data Monitoring Committee for Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO IDE trial [Portico Re-Sheathable Transcatheter Aortic Valve System US IDE Trial], funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population Health Research Institute; honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; vice chair, American College of Cardiology Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI [Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention] clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (editor-in-chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), Population Health Research Institute (COMPASS clinical trial steering committee funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/ treasurer), and WebMD (CME steering committees); other support from Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART (VA Clinical Assessment Reporting and Tracking) Research and Publications Committee (chair); research funding from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company; royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); site coinvestigator for Biotronik, Boston Scientific, St. Jude Medical (now Abbott), and Svelte; trustee for the American College of Cardiology; and unfunded research for FlowCo, Merck, PLx Pharma, and Takeda. Funding Information: Editorial assistance, limited to formatting and collation of coauthor comments, was supported financially by Novo Nordisk and provided by Nathan Ley and Catherine Jones of Watermeadow Medical, an Ashfield Company, part of UDG Healthcare plc, during preparation of this article. Drs Verma, Bhatt, Mazer, and Leiter wrote the first draft. The authors were fully responsible for all content and editorial decisions, were involved in all stages of article development, and have approved the final version.

PY - 2018

Y1 - 2018

KW - Diabetes mellitus

KW - Liraglutide

UR - http://www.scopus.com/inward/record.url?scp=85055606411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055606411&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.036862

DO - 10.1161/CIRCULATIONAHA.118.036862

M3 - Letter

C2 - 30354517

AN - SCOPUS:85055606411

SN - 0009-7322

VL - 138

SP - 1605

EP - 1607

JO - Circulation

JF - Circulation

IS - 15

ER -